178 related articles for article (PubMed ID: 30092727)
1. Scientific and Regulatory Policy Committee Points to Consider: Histopathologic Evaluation in Safety Assessment Studies for PEGylated Pharmaceutical Products.
Irizarry Rovira AR; Bennet BM; Bolon B; Braendli-Baiocco A; Chandra S; Fleurance R; Garman R; Hutto D; Lane J; Romeike A; Sargeant A; Zimmerman B
Toxicol Pathol; 2018 Aug; 46(6):616-635. PubMed ID: 30092727
[TBL] [Abstract][Full Text] [Related]
2. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
Ivens IA; Achanzar W; Baumann A; Brändli-Baiocco A; Cavagnaro J; Dempster M; Depelchin BO; Rovira AR; Dill-Morton L; Lane JH; Reipert BM; Salcedo T; Schweighardt B; Tsuruda LS; Turecek PL; Sims J
Toxicol Pathol; 2015 Oct; 43(7):959-83. PubMed ID: 26239651
[TBL] [Abstract][Full Text] [Related]
3. PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.
Turecek PL; Bossard MJ; Schoetens F; Ivens IA
J Pharm Sci; 2016 Feb; 105(2):460-475. PubMed ID: 26869412
[TBL] [Abstract][Full Text] [Related]
4. Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein.
Fletcher AM; Tellier P; Douville J; Mansell P; Graziano MJ; Mangipudy RS; Brodie TA; Achanzar WE
Toxicol Lett; 2019 Dec; 317():120-129. PubMed ID: 31580884
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance and Ultrastructural Characterization of PEGylation-associated Vacuolation in Nonclinical Models.
Forest T; Xu Q; Kuruvilla S; Vu H; Vlasakova K; Glaab WE; Hines C; Xun S
Toxicol Pathol; 2017 Jul; 45(5):604-613. PubMed ID: 28673196
[TBL] [Abstract][Full Text] [Related]
6. High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins.
Rudmann DG; Alston JT; Hanson JC; Heidel S
Toxicol Pathol; 2013; 41(7):970-83. PubMed ID: 23788571
[TBL] [Abstract][Full Text] [Related]
7. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates.
Stidl R; Fuchs S; Bossard M; Siekmann J; Turecek PL; Putz M
Haemophilia; 2016 Jan; 22(1):54-64. PubMed ID: 26219204
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical Safety Assessment of a Long-Acting Recombinant PEGylated Factor Eight (BAY 94-9027) With a 60 kDa PEG.
Ivens IA; Banczyk D; Gutberlet K; Jackman S; Vauléon S; Frisk AL
Toxicol Pathol; 2019 Jul; 47(5):585-597. PubMed ID: 31132933
[TBL] [Abstract][Full Text] [Related]
9. Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action.
Byrd RA; Blackbourne JL; Knadler MP; Schultze AE; Vahle JL
Toxicol Pathol; 2017 Apr; 45(3):402-415. PubMed ID: 28421968
[TBL] [Abstract][Full Text] [Related]
10. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins.
Bendele A; Seely J; Richey C; Sennello G; Shopp G
Toxicol Sci; 1998 Apr; 42(2):152-7. PubMed ID: 9579027
[TBL] [Abstract][Full Text] [Related]
11. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies.
Webster R; Didier E; Harris P; Siegel N; Stadler J; Tilbury L; Smith D
Drug Metab Dispos; 2007 Jan; 35(1):9-16. PubMed ID: 17020954
[TBL] [Abstract][Full Text] [Related]
12. Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies.
Keirstead ND; Janovitz EB; Meehan JT; LeRoy BE; Megill JR; Peterson RA; Masson RG; Marxfeld HA
Toxicol Pathol; 2019 Jun; 47(4):461-468. PubMed ID: 31018785
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic consequences of pegylation.
Hamidi M; Azadi A; Rafiei P
Drug Deliv; 2006; 13(6):399-409. PubMed ID: 17002967
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?
Baumann A; Tuerck D; Prabhu S; Dickmann L; Sims J
Drug Discov Today; 2014 Oct; 19(10):1623-31. PubMed ID: 24929223
[TBL] [Abstract][Full Text] [Related]
15. Recent development of poly(ethylene glycol)-cholesterol conjugates as drug delivery systems.
He ZY; Chu BY; Wei XW; Li J; Edwards CK; Song XR; He G; Xie YM; Wei YQ; Qian ZY
Int J Pharm; 2014 Jul; 469(1):168-78. PubMed ID: 24768727
[TBL] [Abstract][Full Text] [Related]
16. Safety Assessment of PEG-150 Pentaerythrityl Tetrastearate as Used in Cosmetics.
Johnson W; Bergfeld WF; Belsito DV; Hill RA; Klaassen CD; Liebler DC; Marks JG; Shank RC; Slaga TJ; Snyder PW; Andersen FA; Heldreth B
Int J Toxicol; 2018; 37(2_suppl):5S-9S. PubMed ID: 30235960
[TBL] [Abstract][Full Text] [Related]
17. Final report on the safety assessment of Triethylene Glycol and PEG-4.
Int J Toxicol; 2006; 25 Suppl 2():121-38. PubMed ID: 17090481
[TBL] [Abstract][Full Text] [Related]
18. Final report of the amended safety assessment of PEG-5, -10, -16, -25, -30, and -40 soy sterol.
Int J Toxicol; 2004; 23 Suppl 2():23-47. PubMed ID: 15513823
[TBL] [Abstract][Full Text] [Related]
19. PEGylation: an approach for drug delivery. A review.
Jain A; Jain SK
Crit Rev Ther Drug Carrier Syst; 2008; 25(5):403-47. PubMed ID: 19062633
[TBL] [Abstract][Full Text] [Related]
20. PEG - a versatile conjugating ligand for drugs and drug delivery systems.
Kolate A; Baradia D; Patil S; Vhora I; Kore G; Misra A
J Control Release; 2014 Oct; 192():67-81. PubMed ID: 24997275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
